Extrapancreatic Effect of Glucagon like Peptide-1.
10.3904/kjm.2015.89.4.404
- Author:
In Kyung JEONG
1
Author Information
1. Department of Endocrinology & Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. jik1016@dreamwiz.com
- Publication Type:Review
- Keywords:
Glucagon-like peptide 1;
Cardiovascular system;
Gastrointestinal system;
Brain;
Kidney
- MeSH:
Adipose Tissue;
Animals;
Appetite;
Blood Vessels;
Bone Density;
Brain;
Cardiac Output;
Cardiovascular System;
Enteroendocrine Cells;
Gastrointestinal Motility;
Gastrointestinal Tract;
Glucagon*;
Glucagon-Like Peptide 1;
Heart;
Incretins;
Insulin;
Islets of Langerhans;
Kidney;
Liver;
Lung;
Pancreas;
Weight Loss;
Glucagon-Like Peptide-1 Receptor
- From:Korean Journal of Medicine
2015;89(4):404-412
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Glucagon like peptide-1 (GLP-1) is an intestinal L cell derived incretin hormone which stimulates insulin secretion of beta cell and inhibits glucagon secretion of alpha cell of pancreatic islets. GLP-1 receptors are located in pancreas as well as in a wide variety of tissue such as gastrointestinal tract, heart, blood vessel, lung, brain, kidney, and bone. Therefore GLP-1 and GLP-1 based treatment have multiple extrapancreatic effects which are inhibition of gastrointestinal motility, reduction of appetite, weight loss, increase of cardiac output, cardiovascular protection, neuroprotection, renoprotection, and increase of bone mineral density. Recently, besides GLP-1 receptor dependent pathway, GLP-1 receptor independent pathway has been identified in the extrapancreatic effect of GLP-1 in liver, adipose tissue, muscle, cardiovascular system. This review provides an overview of the pleiotropic effect of GLP-1 in the extrapancreatic organ through review of animal and clinical research.
